AL-DAWAA MEDICAL SERVICES COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.8 SAR | -1.63% |
|
-3.40% | -14.18% |
| Apr. 30 | Aldawaa Medical Services Posts Higher Q1 Net Profit, Revenue | MT |
| Apr. 30 | Al-Dawaa Medical Services Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Drug Retailers
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -14.18% | 2.09B | - | ||
| -29.72% | 15.43B | B- | ||
| -21.99% | 12.31B | B | ||
| -23.58% | 6.59B | B | ||
| +12.34% | 6.3B | C | ||
| -6.55% | 5.88B | C+ | ||
| -1.17% | 4.74B | D- | ||
| +60.03% | 4.7B | C | ||
| -5.50% | 4.03B | B | ||
| -8.59% | 3.58B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4163 Stock
- Ratings Al-Dawaa Medical Services Company